<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36807504</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1399</StartPage><EndPage>1402</EndPage><MedlinePgn>1399-1402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14613</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Xin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-7385-4491</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zerui</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-9364-5590</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Guangtao</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5975-3785</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Miaomiao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1666-4402</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qingrui</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-8298-2148</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hongling</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4224-4244</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Min</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7659-4074</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82001744</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722462">telitacicept</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>11</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36807504</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14613</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, f or the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2022;58(1):23-32.</Citation></Reference><Reference><Citation>Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016;56:948-959.</Citation></Reference><Reference><Citation>Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging. 2007;24(9):701-715.</Citation></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.</Citation></Reference><Reference><Citation>Jesus D, Larosa M, Henriques C, et al. Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis. 2021;80(12):1568-1574.</Citation></Reference><Reference><Citation>Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus. 2022;31(8):998-1006.</Citation></Reference><Reference><Citation>Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017;56(suppl_1):i114-i122.</Citation></Reference><Reference><Citation>Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321-1326.</Citation></Reference><Reference><Citation>Dutta S, Breslin A, Ahmad Y, eds. Tacrolimus in rheumatoid arthritis: a safe and effective DMARD. Annual Meeting of the British-Society-Rheumatology/Spring Meeting of; 2010.</Citation></Reference><Reference><Citation>Chu VT, Enghard P, Sch&#xfc;rer S, Steinhauser G, Berek C. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2010;60(7):2083-2093.</Citation></Reference><Reference><Citation>Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-373.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>